Dyne Therapeutics plans public offering of $200 million in common stock.

From GlobeNewswire: 2025-06-30 16:05:00

Dyne Therapeutics, Inc. (Nasdaq: DYN) has announced a public offering of $200,000,000 of common stock. The underwriters may purchase an additional $30,000,000 of shares. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are managing the offering. The company focuses on treating neuromuscular diseases. The offering is subject to market conditions and SEC approval. The company’s goal is to improve the lives of those with genetic diseases affecting muscle and the nervous system, with clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for other diseases.



Read more at GlobeNewswire: Dyne Therapeutics Announces Proposed Public Offering of